Literature DB >> 11882907

Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma.

H Kaya1, T Ragazzini, E Aribal, I Güney, E Kotiloglu.   

Abstract

Genomic amplification and oncoprotein overexpression of Her-2/neu was studied on ultrasound core needle biopsy specimens of the infiltrative ductal carcinomas of the breast. We performed two colour fluorescence in situ hybridization (FISH) for Her-2/neu and chromosome 17 and compared the FISH results with the immunohistochemical overexpression of Her-2/neu protein by 2 antibodies (DAKO HercepTest and the BioGenex monoclonal antibody AM 134-5M). Furthermore, following radical mastectomy with axillary dissection, Her-2/neu status of the patients were compared with the well known histopathological prognostic factors such as histologic grade, tumor stage, lympho/ vascular invasion, surgical margin status and Paget s disease. Amplification was demonstrated 27% of the cases. Her-2/neu protein overexpression was detected in 47% and 80% of the cases with CB11 and HercepTest respectively. We revealed statistically significant association between the tumor, oncoprotein expression and oncogene amplification (p<0.05). The results of our study showed that combination of IHC and FISH methods enhances the evaluation of tumor genetics at both gene and protein level for the analysis of Her-2/neu in breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11882907     DOI: 10.1007/bf03032384

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  21 in total

1.  Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.

Authors:  R R Tubbs; J D Pettay; P C Roche; M H Stoler; R B Jenkins; T M Grogan
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Authors:  M F Press; L Bernstein; P A Thomas; L F Meisner; J Y Zhou; Y Ma; G Hung; R A Robinson; C Harris; A El-Naggar; D J Slamon; R N Phillips; J S Ross; S R Wolman; K J Flom
Journal:  J Clin Oncol       Date:  1997-08       Impact factor: 44.544

3.  The role of stereotactic biopsy in assessment of nonpalpable breast lesions.

Authors:  J E Wallace; C Sayler; N G McDowell; H S Moseley
Journal:  Am J Surg       Date:  1996-05       Impact factor: 2.565

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use.

Authors:  A Bánkfalvi; R Simon; B Brandt; H Bürger; I Vollmer; B Dockhorn-Dworniczak; R J Lellé; W Boecker
Journal:  Histopathology       Date:  2000-11       Impact factor: 5.087

6.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

Authors:  G Pauletti; W Godolphin; M F Press; D J Slamon
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

Review 7.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients.

Authors:  A Scorilas; J Yotis; K Stravolemos; D Gouriotis; A Keramopoulos; K Ampela; M Talieri; T Trangas
Journal:  Anticancer Res       Date:  1995 Jul-Aug       Impact factor: 2.480

10.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

Authors:  M F Press; G Hung; W Godolphin; D J Slamon
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

View more
  2 in total

1.  An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer.

Authors:  Rachelle L Dillon; Stephen T Brown; Chen Ling; Toshishiro Shioda; William J Muller
Journal:  Mol Cell Biol       Date:  2007-10-15       Impact factor: 4.272

2.  Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer.

Authors:  Susanne Taucher; Margaretha Rudas; Robert M Mader; Michael Gnant; Peter Dubsky; Sebastian Roka; Thomas Bachleitner; Daniela Kandioler; Günther Steger; Martina Mittlböck; Raimund Jakesz
Journal:  Wien Klin Wochenschr       Date:  2004-01-31       Impact factor: 2.275

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.